Study guide

1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders

NBCRNA CRNA Certified Registered Nurse Anesthetist NCE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology

1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders

2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems

2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms

3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives

3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology

4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics

4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics

5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies

5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout

6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators

6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging

7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation

7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways

8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety

8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety

9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation

9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication

10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring

10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies

11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms

11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)

12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA

12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm

13 Chapter 13: Regional Anesthesia: Neuraxial Blocks

13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma

14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance

14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols

15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice

15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives

16 Chapter 16: Obstetric & Gynecologic Anesthesia

16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient

17 Chapter 17: Pediatric Anesthesia

17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm

18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia

18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols

19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia

19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction

20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia

20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation

21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology

21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements

22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology

22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices

23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures

23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases

24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control

24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure

25 Chapter 25: Neurosurgical Subspecialty Procedures

25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy

26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia

26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery

27 Chapter 27: Orthopedic & Extremity Anesthesia

27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block

28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy

28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia

29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients

29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient

1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders

Key Takeaways Explain This Topic AI

Cerebral blood flow (CBF ≈ 50 mL/100g/min) is autoregulated between Mean Arterial Pressures (MAP) of 50-150 mmHg; the curve shifts to the right in chronic hypertension.

CBF changes linearly by 1-2 mL/100g/min per 1 mmHg change in PaCO₂ between 20-80 mmHg; hyperventilation (PaCO₂ 30-35 mmHg) provides rapid, transient reduction in ICP.

Cerebral Perfusion Pressure is calculated as CPP = MAP - ICP (or CVP, whichever is higher); normal adult ICP is 5-15 mmHg, and target CPP during neurotrauma is 60-70 mmHg.

Autonomic hyperreflexia occurs in spinal cord injuries at or above T6 in response to cutaneous or visceral stimulation below the lesion, producing severe hypertension with reflex bradycardia.

Myasthenia Gravis involves postsynaptic nicotinic AChR destruction (resistant to succinylcholine, exquisitely sensitive to non-depolarizers), whereas Lambert-Eaton involves presynaptic VGCC antibodies (sensitive to BOTH depolarizing and non-depolarizing NMBAs).

Last updated: August 2026

1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders

Safe neuroanesthesia and perioperative neurologic care depend on preserving cerebral perfusion pressure, controlling intracranial dynamics, and managing autonomic and neuromuscular junction pathologies.

1. Cerebral Blood Flow (CBF) & Autoregulation

Normal Global CBF: 50 mL / 100 g / min 50 \text{ mL}/100\text{g}/\text{min} 50 mL /100 g / min (approximately 750 mL/min 750 \text{ mL/min} 750 mL/min , or 15 % 15\% 15% of total resting cardiac output).

Cortical Gray Matter: ≈ 80 mL / 100 g / min \approx 80 \text{ mL}/100\text{g}/\text{min} ≈ 80 mL /100 g / min

Subcortical White Matter: ≈ 20 mL / 100 g / min \approx 20 \text{ mL}/100\text{g}/\text{min} ≈ 20 mL /100 g / min

Cerebral Metabolic Rate for Oxygen ( C M R O 2 CMRO_2 CMR O 2 ​ ): 3.0 − 3.5 mL O 2 / 100 g / min 3.0 - 3.5 \text{ mL } O_2/100\text{g}/\text{min} 3.0 − 3.5 mL O 2 ​ /100 g / min (accounts for ≈ 20 % \approx 20\% ≈ 20% of total body resting oxygen consumption). +-------------------------------------------------------------------------+

  • | CEREBRAL BLOOD FLOW AUTOREGULATION |
  • +-------------------------------------------------------------------------+
  • | |
  • | CBF (mL/100g/min) |
  • | 100 | +-----------------------+ (Hyperperfusion) |
  • | | / \ |
  • | 50 |----------------+ AUTOREGULATION PLATEAU +----------------- |
  • | | / (50 - 150 mmHg MAP) \ |
  • | 0 +--------------+-------------------------------+---------> |
  • | 0 50 150 200 |
  • | MAP (mmHg) |
  • +-------------------------------------------------------------------------+
  • Autoregulation Dynamics

Autoregulation Range: In normotensive adults, CBF is maintained constant across Mean Arterial Pressures of 50 − 150 mmHg 50 - 150 \text{ mmHg} 50 − 150 mmHg (or CPP 50 − 150 mmHg 50 - 150 \text{ mmHg} 50 − 150 mmHg ).

Rightward Curve Shift in Chronic Hypertension: Long-standing hypertension causes arteriolar hypertrophy, shifting the autoregulation curve to the right (e.g., 80 − 180 mmHg 80 - 180 \text{ mmHg} 80 − 180 mmHg ). Lowering blood pressure into a "normal" range ( M A P ≈ 65 mmHg MAP \approx 65 \text{ mmHg} M A P ≈ 65 mmHg ) can precipitate cerebral hypoperfusion and ischemic stroke in these patients.

Determinants & Modulators of CBF

P a C O 2 PaCO_2 P a C O 2 ​ Responsiveness: Between P a C O 2 PaCO_2 P a C O 2 ​ of 20 − 80 mmHg 20 - 80 \text{ mmHg} 20 − 80 mmHg , CBF changes in a linear fashion by 1 − 2 mL / 100 g / min 1 - 2 \text{ mL}/100\text{g}/\text{min} 1 − 2 mL /100 g / min per 1 mmHg 1 \text{ mmHg} 1 mmHg change in P a C O 2 PaCO_2 P a C O 2 ​ (or ≈ 2 − 4 % \approx 2 - 4\% ≈ 2 − 4% change in CBF per mmHg).

Hyperventilation ( P a C O 2 30 − 35 mmHg PaCO_2 \; 30 - 35 \text{ mmHg} P a C O 2 ​ 30 − 35 mmHg ): Rapidly lowers ICP via cerebral vasoconstriction. Effects diminish after 12 − 24 hours 12 - 24 \text{ hours} 12 − 24 hours due to renal/CSF bicarbonate buffering. Excessive hyperventilation ( P a C O 2 < 25 mmHg PaCO_2 < 25 \text{ mmHg} P a C O 2 ​ < 25 mmHg ) induces severe cerebral ischemia.

P a O 2 PaO_2 P a O 2 ​ Responsiveness: CBF does not significantly change until P a O 2 PaO_2 P a O 2 ​ falls below 50 − 60 mmHg 50 - 60 \text{ mmHg} 50 − 60 mmHg , at which point profound arterial vasodilation occurs to prevent tissue hypoxia.

Temperature: CBF and C M R O 2 CMRO_2 CMR O 2 ​ decrease by 6 − 7 % 6 - 7\% 6 − 7% for every 1 ∘ C 1^\circ\text{C} 1 ∘ C decrease in brain temperature. At temperatures below 20 ∘ C 20^\circ\text{C} 2 0 ∘ C , the electroencephalogram (EEG) becomes isoelectric.

Anesthetic Agent Effects (Coupling vs. Uncoupling):

IV Anesthetics (Propofol, Etomidate, Barbiturates): Produce coupled reductions in both C M R O 2 CMRO_2 CMR O 2 ​ and CBF, decreasing intracranial blood volume and lowering ICP. (Ketamine is an exception: increases CBF and C M R O 2 CMRO_2 CMR O 2 ​ ) .

Volatile Anesthetics (Isoflurane, Sevoflurane, Desflurane): Cause intrinsic dose-dependent cerebral vasodilation while decreasing C M R O 2 CMRO_2 CMR O 2 ​ . At concentrations > 1.0 MAC >1.0 \text{ MAC} > 1.0 MAC , intrinsic vasodilation overcomes metabolic depression ( uncoupling ), leading to increased CBF and ICP.

2. Intracranial Dynamics & The Monro-Kellie Doctrine +-------------------------------------------------------------------------+

  • | MONRO-KELLIE HYPOTHESIS |
  • +-------------------------------------------------------------------------+
  • | Rigid Skull Vault = Brain Tissue (80%) + Blood (10%) + CSF (10%) |
  • | |
  • | An increase in the volume of one cranial component must be offset |
  • | by a compensatory decrease in another, or ICP will exponentially rise. |
  • +-------------------------------------------------------------------------+

Normal Intracranial Pressure (ICP): 5 − 15 mmHg 5 - 15 \text{ mmHg} 5 − 15 mmHg . Intracranial hypertension is defined as sustained ICP > 20 mmHg >20 \text{ mmHg} > 20 mmHg .

Cerebral Perfusion Pressure (CPP): C P P = M A P − I C P ( or M A P − C V P , whichever is higher ) CPP = MAP - ICP \quad (\text{or } MAP - CVP, \text{ whichever is higher}) CPP = M A P − I CP ( or M A P − C V P , whichever is higher )

Target CPP in Neurological Injury: 60 − 70 mmHg 60 - 70 \text{ mmHg} 60 − 70 mmHg (avoid < 50 mmHg <50 \text{ mmHg} < 50 mmHg to prevent ischemia; avoid > 70 mmHg >70 \text{ mmHg} > 70 mmHg to prevent vasogenic edema and ARDS).

Cushing's Triad

A late, life-threatening manifestation of severely elevated ICP and impending transtentorial herniation:

  • Hypertension (with widened pulse pressure)
  • Bradycardia (reflex vagal response to severe systemic hypertension)
  • Irregular Respirations / Respiratory Depression (brainstem compression)
  • Cerebrospinal Fluid (CSF) Kinetics

Production: Formed by ependymal cells of the choroid plexus at a rate of 0.35 − 0.40 mL/min 0.35 - 0.40 \text{ mL/min} 0.35 − 0.40 mL/min ( ≈ 500 mL/day \approx 500 \text{ mL/day} ≈ 500 mL/day ). Total adult CSF volume is ≈ 150 mL \approx 150 \text{ mL} ≈ 150 mL .

Flow & Absorption: Lateral ventricles → \to → Foramen of Monro → \to → 3rd Ventricle → \to → Cerebral Aqueduct of Sylvius → \to → 4th Ventricle → \to → Foramina of Luschka & Magendie → \to → Subarachnoid space → \to → Absorbed via arachnoid villi/granulations into the superior sagittal sinus.

3. Autonomic Nervous System Receptors & Second Messengers

Receptor G-Protein Primary Second Messenger Primary Organ Locations Physiologic Actions

α 1 \alpha_1 α 1 ​ G q G_q G q ​ ↑ PLC → ↑ I P 3 , D A G , C a 2 + \uparrow \text{PLC} \to \uparrow IP_3, DAG, Ca^{2+} ↑ PLC →↑ I P 3 ​ , D A G , C a 2 + Vascular smooth muscle, radial pupillary muscle, bladder sphincter Vasoconstriction ( ↑ S V R \uparrow SVR ↑ S V R ), mydriasis, urinary retention

α 2 \alpha_2 α 2 ​ G i G_i G i ​ ↓ Adenylyl Cyclase → ↓ c A M P \downarrow \text{Adenylyl Cyclase} \to \downarrow cAMP ↓ Adenylyl Cyclase →↓ c A MP Presynaptic nerve terminals, CNS locus coeruleus, platelets Sympatholysis ( ↓ N E \downarrow NE ↓ NE release), sedation, analgesia, platelet aggregation

β 1 \beta_1 β 1 ​ G s G_s G s ​ ↑ Adenylyl Cyclase → ↑ c A M P \uparrow \text{Adenylyl Cyclase} \to \uparrow cAMP ↑ Adenylyl Cyclase →↑ c A MP SA node, AV node, myocardium, juxtaglomerular cells ↑ \uparrow ↑ Inotropy, ↑ \uparrow ↑ chronotropy, ↑ \uparrow ↑ dromotropy, ↑ \uparrow ↑ renin release

β 2 \beta_2 β 2 ​ G s G_s G s ​ ↑ Adenylyl Cyclase → ↑ c A M P \uparrow \text{Adenylyl Cyclase} \to \uparrow cAMP ↑ Adenylyl Cyclase →↑ c A MP Bronchial smooth muscle, vascular smooth muscle, uterus Bronchodilation, vasodilation, uterine relaxation, hypokalemia ( K + K^+ K + intracellular shift)

β 3 \beta_3 β 3 ​ G s G_s G s ​ ↑ Adenylyl Cyclase → ↑ c A M P \uparrow \text{Adenylyl Cyclase} \to \uparrow cAMP ↑ Adenylyl Cyclase →↑ c A MP Adipose tissue, urinary bladder detrusor Lipolysis, detrusor relaxation (mirabegron)

M 2 M_2 M 2 ​ G i G_i G i ​ ↓ Adenylyl Cyclase , ↑ K + efflux \downarrow \text{Adenylyl Cyclase}, \uparrow K^+ \text{ efflux} ↓ Adenylyl Cyclase , ↑ K + efflux SA and AV nodes of the heart ↓ \downarrow ↓ Heart rate (negative chronotropy), ↓ \downarrow ↓ conduction velocity

M 3 M_3 M 3 ​ G q G_q G q ​ ↑ PLC → ↑ I P 3 , D A G , C a 2 + \uparrow \text{PLC} \to \uparrow IP_3, DAG, Ca^{2+} ↑ PLC →↑ I P 3 ​ , D A G , C a 2 + Bronchial tree, salivary/gastric glands, ciliary muscle Bronchoconstriction, profuse secretions, salivation, miosis

4. Autonomic Dysreflexia (Hyperreflexia)

Etiology: Occurs in patients with spinal cord transection at or above the T6 level (rare below T10) after the acute spinal shock phase has resolved (typically weeks to months post-injury; incidence ≈ 85 % \approx 85\% ≈ 85% in lesions above T6).

Pathophysiologic Cascade:

Cutaneous or visceral noxious stimulation below the cord lesion (most commonly bladder distension ≈ 85 % \approx 85\% ≈ 85% , bowel impaction, surgical manipulation, uterine contractions).

Triggers massive, uninhibited sympathetic discharge from the isolated isolated spinal cord below the level of injury.

Intense splanchnic and peripheral arteriolar vasoconstriction produces severe, paroxysmal systemic hypertension .

Carotid and aortic baroreceptors detect severe hypertension, triggering compensatory vagal efferent discharge → \to → bradycardia and cutaneous vasodilation above the level of the lesion (flushing, diaphoresis, headache, nasal congestion).

Central descending inhibitory impulses are blocked from traversing the injured spinal cord, perpetuating vasoconstriction below T6.

Complications: Intracranial hemorrhage, encephalopathy, seizures, acute pulmonary edema, lethal ventricular arrhythmias.

Anesthetic Management:

General anesthesia or deep spinal anesthesia (which effectively blocks the afferent sensory limb) prevents autonomic hyperreflexia during surgery even in patients with complete sensory loss.

First-line emergency treatment: Remove noxious stimulus, deepen anesthetic depth, and administer rapidly acting vasodilators (sodium nitroprusside, nitroglycerin, nicardipine).

5. Neuromuscular Junction Pathology: Myasthenia Gravis vs. Lambert-Eaton +------------------------------------+-------------------------------------+

  • | MYASTHENIA GRAVIS (MG) | LAMBERT-EATON SYNDROME (LEMS) |
  • +------------------------------------+-------------------------------------+
  • | Postsynaptic AChR Autoantibodies | Presynaptic P/Q-Type VGCC Antibodies|
  • | Weakness WORSENS with exertion | Weakness IMPROVES with exercise |
  • | Associated with Thymoma (75%) | Associated with SCLC (>60%) |
  • | Resistant to Succinylcholine | SENSITIVE to Succinylcholine |
  • | Exquisitely SENSITIVE to NDNMBAs | Exquisitely SENSITIVE to NDNMBAs |
  • +------------------------------------+-------------------------------------+

Diagnostic / Clinical Feature Myasthenia Gravis (MG) Lambert-Eaton Myasthenic Syndrome (LEMS)

Pathologic Site & Mechanism Autoantibodies destroy postsynaptic nicotinic acetylcholine receptors (AChR) (reduces functional receptors by 70 − 80 % 70 - 80\% 70 − 80% ) Autoantibodies destroy presynaptic voltage-gated calcium channels (P/Q-type VGCC) , preventing calcium influx and ACh exocytosis

Clinical Presentation Extraocular/bulbar weakness (ptosis, diplopia, dysphagia); weakness worsens with repetitive exercise and at the end of the day Proximal lower limb weakness; muscle strength improves with repeated contraction ; autonomic dysfunction (dry mouth, orthostasis)

Associated Pathology Thymic hyperplasia ( 65 % 65\% 65% ) or Thymoma ( 10 − 15 % 10 - 15\% 10 − 15% ) Small Cell Lung Carcinoma (SCLC) in > 60 % >60\% > 60% of cases (paraneoplastic)

Response to Succinylcholine RESISTANT (requires higher dose, 1.5 − 2.0 mg/kg 1.5 - 2.0 \text{ mg/kg} 1.5 − 2.0 mg/kg , though anticholinesterase medications can prolong duration) SENSITIVE (marked prolongation of action)

Response to Non-Depolarizers EXQUISITELY SENSITIVE (reduce dose by 50 − 80 % 50 - 80\% 50 − 80% or avoid entirely; Sugammadex is the reversal agent of choice) EXQUISITELY SENSITIVE (reduce dose markedly or avoid; poor response to anticholinesterases)

Pharmacotherapy Pyridostigmine (oral anticholinesterase), corticosteroids, plasmapheresis, IVIG 3,4-Diaminopyridine (Amifampridine: blocks presynaptic K + K^+ K + channels, prolonging action potential), IVIG

Loading diagram... Autonomic Dysreflexia Reflex Arc (Spinal Cord Lesions >= T6)